A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently available drugs often fail to eradicate the virus from the body.Gene-editing therapies — which make cuts to the DNA strands — have been explored but for hepatitis B, they can increase cancer risks. Researchers are turning instead to epigenetic editing, which modifies mar...